PubRank

Richard J Powell

Author PubWeight™ 67.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002 2.10
2 Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2003 1.98
3 Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 2007 1.92
4 Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009 1.81
5 Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003 1.75
6 The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2003 1.57
7 Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 2003 1.51
8 Carotid artery stenting and patient outcomes: the CABANA surveillance study. Catheter Cardiovasc Interv 2014 1.45
9 Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling. J Biol Chem 2007 1.35
10 Anatomic characteristics of ruptured abdominal aortic aneurysm on conventional CT scans: Implications for rupture risk. J Vasc Surg 2004 1.34
11 Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006 1.26
12 Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004 1.23
13 Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004 1.22
14 Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res 2008 1.17
15 Validation of the Society for Vascular Surgery's objective performance goals for critical limb ischemia in everyday vascular surgery practice. J Vasc Surg 2011 1.16
16 Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 2006 1.16
17 Retrograde mesenteric stenting during laparotomy for acute occlusive mesenteric ischemia. J Vasc Surg 2007 1.15
18 The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol 2006 1.12
19 Factors associated with amputation or graft occlusion one year after lower extremity bypass in northern New England. Ann Vasc Surg 2009 1.09
20 Mesenteric stenting for chronic mesenteric ischemia. J Vasc Surg 2005 1.08
21 Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 2004 1.06
22 Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arterioscler Thromb Vasc Biol 2011 1.05
23 Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. Arthritis Rheum 2007 1.01
24 Long-term results of combined common femoral endarterectomy and iliac stenting/stent grafting for occlusive disease. J Vasc Surg 2008 1.00
25 Early discharge does not increase readmission or mortality after high-risk vascular surgery. J Vasc Surg 2012 1.00
26 Neuroprotection during carotid artery stenting using the GORE flow reversal system: 30-day outcomes in the EMPiRE Clinical Study. Catheter Cardiovasc Interv 2010 1.00
27 Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011 0.99
28 Endovascular repair of abdominal aortic aneurysm without preoperative arteriography. J Vasc Surg 2003 0.99
29 Endothelial cell activation of the smooth muscle cell phosphoinositide 3-kinase/Akt pathway promotes differentiation. J Vasc Surg 2005 0.96
30 Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 2003 0.94
31 Outcomes of renal artery angioplasty and stenting using low-profile systems. J Vasc Surg 2005 0.92
32 Prevalence and clinical significance of stent fracture and deformation following carotid artery stenting. J Vasc Surg 2011 0.92
33 Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery. J Vasc Surg 2011 0.92
34 The eye in systemic inflammatory diseases. Lancet 2004 0.91
35 Long-term results of open and endovascular revascularization of superficial femoral artery occlusive disease. J Vasc Surg 2011 0.91
36 Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line. Arthritis Rheum 2009 0.91
37 A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS). Eur J Immunol 2014 0.90
38 Disseminated Mycobacterium tuberculosis infection due to interferon gamma deficiency. Response to replacement therapy. Thorax 2007 0.89
39 Current status of carotid artery stenting. J Vasc Surg 2006 0.89
40 Early results of stent-grafting to treat diffuse aortoiliac occlusive disease. J Vasc Surg 2003 0.88
41 A truncated plasminogen activator inhibitor-1 protein blocks the availability of heparin-binding vascular endothelial growth factor A isoforms. J Biol Chem 2002 0.87
42 Blinded comparison of preoperative duplex ultrasound scanning and contrast arteriography for planning revascularization at the level of the tibia. J Vasc Surg 2003 0.86
43 Hyperoxia enhances VEGF release from A549 cells via post-transcriptional processes. Free Radic Biol Med 2007 0.86
44 Human autologous mixed lymphocyte reaction as an in vitro model for autoreactivity to apoptotic antigens. Immunology 2002 0.85
45 Role of ciclosporin in steroid-responsive sudden sensorineural hearing loss. Acta Otolaryngol 2005 0.85
46 "Medical high risk" designation is not associated with survival after carotid artery stenting. J Vasc Surg 2007 0.85
47 Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR. Am J Physiol Cell Physiol 2010 0.84
48 Shifting Wallgraft position: case reports and review of the forces affecting Wallgraft positioning. J Vasc Surg 2006 0.84
49 Carotid artery stenting: what have we learned from the clinical trials and registries and where do we go from here? Ann Vasc Surg 2008 0.84
50 Brain injury after carotid revascularization: outcomes, mechanisms, and opportunities for improvement. Ann Vasc Surg 2010 0.83
51 Elevated CD16 expression by monocytes from patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2007 0.83
52 Hyperoxia alters the expression and phosphorylation of multiple factors regulating translation initiation. Am J Physiol Lung Cell Mol Physiol 2004 0.83
53 Early results of external iliac artery stenting combined with common femoral artery endarterectomy. J Vasc Surg 2002 0.82
54 Restenosis in gold-coated renal artery stents. J Vasc Surg 2005 0.82
55 Functional outcomes following catheter-based iliac vein stent placement. Vasc Endovascular Surg 2013 0.82
56 The value of 3D-CT angiographic assessment prior to carotid stenting. J Vasc Surg 2009 0.82
57 Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol 2009 0.81
58 Lean principles optimize on-time vascular surgery operating room starts and decrease resident work hours. J Vasc Surg 2013 0.81
59 The impact of adjunctive iliac stenting on femoral-femoral bypass in contemporary practice. J Vasc Surg 2012 0.81
60 Internal iliac occlusion without coil embolization during endovascular abdominal aortic aneurysm repair. J Vasc Surg 2002 0.81
61 Cost determinants of percutaneous and surgical interventions for treatment of intermittent claudication from the perspective of the hospital. Cardiovasc Intervent Radiol 2007 0.80
62 The effect of endothelial cell overexpression of plasminogen activator inhibitor-1 on smooth muscle cell migration. J Vasc Surg 2002 0.80
63 Prediction of early graft failure with intraoperative completion duplex ultrasound scan. J Vasc Surg 2002 0.77
64 Management of carotid injuries in a hostile neck using endovascular grafts. J Vasc Surg 2004 0.75
65 Clinical effectiveness of secondary interventions for restenosis after renal artery stenting. J Vasc Surg 2013 0.75
66 Heterogeneity of tumor necrosis factor receptor-associated periodic syndrome: comment on the article by Siebert et al. Arthritis Rheum 2005 0.75
67 Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions. BMC Cardiovasc Disord 2014 0.75
68 Stent graft repair of iatrogenic femoral arteriovenous fistula: a useful therapeutic approach in a hostile groin. Vasc Endovascular Surg 2009 0.75
69 Embolic stroke after carotid stenting: microscopic computed tomography analysis of en bloc surgical specimen demonstrating ulceration. Circulation 2010 0.75